Chapter Four

Global Stem Cell Collaboration and Licensing Agreements Analysis Report 2023: Breakdown by Company A-Z, Deal Type, Therapeutic Target and Upfront, Milestone, Royalties Data - ResearchAndMarkets.com

Retrieved on: 
星期一, 十一月 20, 2023
Biotechnology, Health, Stem Cells, Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Mobile phone, Veterinary medicine, Risk management, Fine chemical, Property management, Commercial property, Lease

Stem Cell Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the stem cell deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Stem Cell Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the stem cell deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of stem cell deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter stem cell deals.
  • The report also includes numerous table and figures that illustrate the trends and activities in stem cell deal making since 2016.

Global Biomarker Collaboration and Licensing Partnering Analysis Report 2023: Gain an Understanding and Analysis of How and Why Companies Enter Deals - ResearchAndMarkets.com

Retrieved on: 
星期五, 十一月 17, 2023
Biotechnology, Pharmaceutical, Health, Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Chapter Three, Directory, Chapter One, Pharmaceutical industry, Risk management, Real estate, Property management, Commercial property, Lease

Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of biomarker deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter biomarker deals.
  • The report also includes numerous table and figures that illustrate the trends and activities in biomarker deal making since 2016.

Global Genomic Collaboration and Licensing Agreements Analysis Report 2023 with Directory of 857 Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
星期五, 十一月 17, 2023
Genetics, Science, Health, Research, Record, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Vaccine, Pharmaceutical industry, Risk management, Real estate, Property management, Commercial property, Lease

Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of genomic deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter genomic deals.
  • The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2016.

Regenerative Medicine Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of 1,651 Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
星期三, 十一月 15, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Regenerative medicine, Record, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Chapter Three, Directory, Chapter One, Veterinary medicine, Risk management, Real estate, Property management, Commercial property, Lease

This report contains a comprehensive listing of 1651 regenerative medicine deals announced since 2016 including financial terms where available, including links to online deal records of actual regenerative medicine partnering deals as disclosed by the deal parties.

Key Points: 
  • This report contains a comprehensive listing of 1651 regenerative medicine deals announced since 2016 including financial terms where available, including links to online deal records of actual regenerative medicine partnering deals as disclosed by the deal parties.
  • Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the regenerative medicine deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of regenerative medicine deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine deals.

Global Viral Vector Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of 377 Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
星期三, 十一月 15, 2023
Health, Genetics, Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Vaccine, Risk management, Commercial property, Lease, Property management

This report contains a comprehensive listing of 377 viral vector deals announced since 2016 including financial terms where available including links to online deal records of actual viral vector partnering deals as disclosed by the deal parties.

Key Points: 
  • This report contains a comprehensive listing of 377 viral vector deals announced since 2016 including financial terms where available including links to online deal records of actual viral vector partnering deals as disclosed by the deal parties.
  • Viral Vector Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the viral vector deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of viral vector deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter viral vector deals.

Global Diagnostics Distribution Deals Analysis Report 2023 with Focus on the Top 25 Most Active Distribution Dealmaker Companies

Retrieved on: 
星期二, 十二月 12, 2023
Confidentiality, Mecum Dealmakers, Chapter, Directory, Chapter Five, A-Z, Chapter Four, Orientation, Chapter Three, Chapter One, Risk management, Commercial property, Cryptocurrency, Publishing, Lease, Property management

DUBLIN, Dec. 12, 2023 /PRNewswire/ -- The "Distribution Deals in Diagnostics 2016 to 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 12, 2023 /PRNewswire/ -- The "Distribution Deals in Diagnostics 2016 to 2023" report has been added to ResearchAndMarkets.com's offering.
  • Fully revised and updated, the report provides details of distribution deals from 2016 to 2023.
  • Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals.
  • Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies.

Global Stem Cell Collaboration and Licensing Agreements Analysis Report 2023 with Directory of 150+ Deals Signed Since 2016

Retrieved on: 
星期六, 十一月 18, 2023
Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Mobile phone, Veterinary medicine, Risk management, Fine chemical, Property management, Commercial property, Lease

DUBLIN, Nov. 17, 2023 /PRNewswire/ -- The "Stem Cell Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 17, 2023 /PRNewswire/ -- The "Stem Cell Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.
  • Stem Cell Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the stem cell deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of stem cell deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter stem cell deals.

World Gynecology Collaboration and Licensing Agreements Analysis Report 2023 with Directory of Deals Signed Since 2016

Retrieved on: 
星期六, 十一月 18, 2023
Confidentiality, Gynaecology, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Commercial property, Cryptocurrency, Risk management, Property management, Lease

DUBLIN, Nov. 17, 2023 /PRNewswire/ -- The "Gynecology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 17, 2023 /PRNewswire/ -- The "Gynecology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.
  • Gynecology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gynecology deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of gynecology deals from 2016 to 2023.
  • The report also includes numerous table and figures that illustrate the trends and activities in gynecology deal making since 2016.

Global Hematology Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of Deals Signed Since 2016

Retrieved on: 
星期五, 十一月 17, 2023
Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Music, Property management, Commercial property, Cryptocurrency, Publishing, Lease, Risk management

DUBLIN, Nov. 16, 2023 /PRNewswire/ -- The "Hematology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 16, 2023 /PRNewswire/ -- The "Hematology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.
  • Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.
  • This fully revised and updated report offers comprehensive details of hematology deals spanning from 2016 to 2023.
  • This report includes a comprehensive listing of collaboration and licensing deals announced since 2016, sourced from the Current Agreements deals and alliances database.

Pharmaceuticals and Biotechnology Manufacturing and Supply Deals Analysis Report 2023 with Focus on the Top 25 Most Active Dealmakers Since 2019 - ResearchAndMarkets.com

Retrieved on: 
星期四, 九月 21, 2023
Biotechnology, Manufacturing, Other Manufacturing, Health, Pharmaceutical, Chapter Four, Directory, A-Z, Orientation, Confidentiality, Chapter Three, Chapter One, Chapter, Chapter Five, Chapter Six, Fine chemical, Risk management, Commercial property, Cryptocurrency, Real estate, Publishing, Lease, Property management

The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter manufacturing and supply deals.
  • Fully revised and updated, the report provides details of manufacturing and supply deals from 2019 to 2023.
  • The report provides access to manufacturing and supply deal payment terms as announced between the parties.